Cytopoint (30 - 40 kg)
Active substance
ATC code
Species
Dogs.
Indications
Treatment of pruritus associated with allergic dermatitis in dogs.
Treatment of clinical manifestations of atopic dermatitis in dogs.
Dose to be administered and administration route
Subcutaneous use.
Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the vial.
Dose according to the dosing chart below. For dogs above 40 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering.
Dosage and treatment schedule:
The recommended minimum dose is 1 mg/kg bodyweight, once a month. The need for repeat or longer-term treatment in dogs with allergic dermatitis should be based on the needs of the individual patient including an assessment by the responsible veterinarian of the ability to avoid/eliminate the allergenic stimulus (see also section 4.5). Dose according to the dosing chart below:
|
CYTOPOINT strength (mg) and number of vials to be administered |
||||
|
Bodyweight (kg) of dog |
10 mg |
20 mg |
30 mg |
40 mg |
|
3.0-10.0 |
1 |
|||
|
10.1-20.0 |
1 |
|||
|
20.1-30.0 |
1 |
|||
|
30.1-40.0 |
1 |
|||
|
40.1-50.0 |
1 |
1 |
||
|
50.1-60.0 |
2 |
|||
|
60.1-70.0 |
1 |
1 |
||
|
70.1-80.0 |
2 |
|||
Adverse reactions
Dogs:
|
Rare (1 to 10 animals / 10,000 animals treated): |
Hypersensitivity reaction1 (anaphylaxis, facial oedema, urticaria) Vomiting2, diarrhoea2 Neurological signs (ataxia, convulsion, seizure) |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Injection site pain, injection site swelling Clinical signs of immune mediated diseases (e.g. immune-mediated haemolytic anaemia, immunemediated thrombocytopenia) |
1 In case of such reactions, appropriate treatment should be administered immediately.
2 May occur in connection with hypersensitivity reactions. Treatment should be administered as needed.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for contact details.
